General Electric's stock has been on a terrible run. It will take more than one bullish analyst to turn this stock around for good.
More than 1,500 children were admitted to hospitals for opioid overdoses between 2012 and 2015.
Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?
These biotech names are all great buys on dips. Notably Celgene, which is fresh off a terrible trading session.
The company is making a variety of drinkable cannabis products.
Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.
There are still skeptics when it comes to Valeant Pharmaceuticals -- and for good reason.
The company is marketing arm and joint enhancement products.
The pharmaceutical company unveiled a collaboration and license pact with Revance Therapeutics to develop and commercialize a proposed biosimilar or copy of Allergan's Botox.
Jim Cramer questions whether Celgene overpaid in its $7.2 billion deal for Receptos.
Johnson & Johnson may be down, but don't count it out.
The Food and Drug Administration determined that the nonclinical and clinical pharmacology sections in the new drug application "were insufficient to permit a complete review," Celgene said.
The news from the tech giant comes a month after Amazon, Berkshire Hathaway and JPMorgan unveiled a joint healthcare initiative.
Could Amazon be lost in the jungle when it comes to the drug supply chain? RBC analysts say it's possible. Don't count on a big entrance for at least a few years.
Allergan's losing streak in a bid to stash patent rights protecting cash cow Restasis remains intact as the U.S. Patent Trial and Appeal Board rejects a move to dismiss a challenge brought by a trio of pharma companies.